USFDA finds 11 observations at Granules India site
In short
USFDA inspectors found 11 observations at Granules India’s Gagillapur facility in Hyderabad. The inspection ran from October 19 to October 30, and the company said there was no impact on manufacturing or distribution from the site.
This matters because the plant makes finished-dose medicines, but the reporting does not say what the observations were or what the USFDA will do next.
What the reporting says
USFDA inspectors found 11 observations at Granules India’s Gagillapur finished-dosage facility in Hyderabad during an inspection from October 19 to October 30. The reporting says the company stated there was no impact on manufacturing or distribution from the site. The full details of the observations and any follow-up action were not stated in the available reporting.
Why it matters
USFDA inspectors reported 11 observations at Granules India’s Gagillapur finished-dosage facility in Hyderabad after an inspection from October 19 to October 30. The company said there was no impact on manufacturing or distribution from the site. The reporting does not state the nature of the observations, whether they require remediation, or whether they could affect future regulatory clearance.